Drug Approval | July 01, 2022
Zydus receives final approval from USFDA for Lacosamide injection
Lacosamide Injection is used to treat partial-onset seizures.
Lacosamide Injection is used to treat partial-onset seizures.
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Alopecia areata usually presents as a few small bald patches in the head
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Subscribe To Our Newsletter & Stay Updated
